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in the case of UC. CONCLUSIONS: These preliminary results show that this innova-
tive cost estimation, obtained with this carefully controlled use of population wide 
databases, is a valuable alternative to traditional analyses obtained with ad hoc 
designed and less representative protocols.
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OBJECTIVES: Obesity is becoming to be treated like a worldwide epidemic. In Poland 
about 10.6% employees are obese. The objective of the studies was to estimate the 
indirect costs of obesity among Polish society. METHODS: Human Capital Approach 
method was used in costs quantifying. Data were collected from obese Polish employ-
ees. Work Productivity and Activity Impairment General Health questionnaire was 
used to estimate absenteeism and presenteeism in obese population. Indirect cost for 
general population was calculated on the basis of gross value added per employee in 
2008. Central Statistical Ofﬁ ce (GUS) data were used to identify obese epidemiology 
in employed population. Values are presented in Euro (exchange rate: 1 EUR = 4.10 
PLN). RESULTS: Data from 96 people were analyzed (mean age = 41.7 years, 34.4% 
men, average BMI = 34.2 kg/m2). Overall work impairment due to health problems 
in questioned population was estimated at 36.3%, with 11.8% of work time missed 
due to health problems. Taking into consideration that based on GUS data near 1.5 
million employees are obese total indirect costs of obesity in Poland in the year 2008 
were estimated at c10,5 billion representing 0.9% of gross domestic product. Absen-
teeism costs accounted for less than 1/3 of this costs (c3.4 billion) while pressenteism 
costs were estimated at amount of c7.0 billion. We didn’t ﬁ nd any correlation between 
BMI score and work impairment due to health problems (Pearson r = 0,15). 
CONCLUSIONS: Previously estimated direct medical costs of obesity (without obesity 
related diseases) covered by public payer were quantiﬁ ed at 4 million EUR in the year 
2008. We’ve found that indirect costs of lost productivity due to obesity are substantial 
to polish economy. However we conclude that not obesity itself but obesity related 
diseases generate most of indirect costs.
PSY23
COST OF POMPE DISEASE IN POLAND IN 2008 AND 2009
Baran A, Czech M, Hermanowski T
Medical University of Warsaw, Warsaw, Poland
OBJECTIVES: The objective of this review is to estimate the direct and indirect costs 
of Pompe disease. METHODS: Direct and indirect cots were estimated based on a 
questionnaire (consisting of 108 questions) measuring costs speciﬁ c for Pompe disease 
and a survey concerning the enzyme replacement therapy created for the research. The 
direct costs of Pompe disease were estimated from the patient`s social and the public 
health care system payer (National Health Fund) perspectives. While estimating indi-
rect costs human capital approach methodology was used taking into consideration 
absence from work due to the illness, lost time and salaries of the members of the 
family taking care of the patients. The analysis was done in a 2-year time span. 
RESULTS: In the research 80% of Pompe disease population were studied (N = 16). 
Indirect costs constituted 3% of the total cost (c17,959,67 per patient in the period 
of 2 years). The highest component of the amount was the cost of the income lost by 
the members of the families taking care of the patients; 96% of the total direct costs 
were the direct medical costs (c550,975.03 per patient in the period of 2 years). The 
main direct medical cost determinant is the enzyme therapy (c543,350.47)-constituting 
99% of the total direct medical costs. CONCLUSIONS: Providing patients with the 
prompt access to the enzyme replacement therapy result in lowering future indirect 
and direct costs: smaller number of patients taking disability pension, lower cost of 
medical equipment used by patients and higher productivity of patients able to work. 
Additionally there is a need to introduce an unusual and untypical approach in Health 
Technology Assessment.
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OBJECTIVES: To estimate the cost of care for CML in patients with resistance and/
or intolerance to imatinib from the public perspective in Mexico METHODS: Retro-
spective study of 208 patients diagnosed with CML, ≥18 years of age, treated with 
imatinib and having at least 12 months follow-up with ﬁ nal contact in the past three 
months, whom were attended at 6 tertiary level public hospitals in Mexico. Cost of 
care data captured includes drug costs (chemotherapy and imatinib), inpatient visits, 
toxicity treatment, and medical monitoring (labs studies, outpatient visits and other 
drugs costs). Costs are estimated on a monthly basis and are classiﬁ ed according to 
the presence of failure (toxicity or resistance to imatinib). Descriptive statistics on the 
use of resources are reported. RESULTS: At diagnosis of CML, 95% of patients were 
in chronic phase and 5% in accelerated phase. Fifty-ﬁ ve percent were female, with a 
mean age of 48.30. Deﬁ ning treatment failure as any imatinib dose adjustment, increas-
ing if resistance (lack of hematological and/or cytogenetic response) or reduction if 
intolerance (toxicity), 84.7% of patients failed initial treatment with imatinib. The 
median time to imatnib dose adjustment was 5.1 months. The average monthly cost of 
diagnosis and treatment prior to receiving imatinib was estimated US$2,210.54 ($2461–
$2808); the average monthly cost during treatment of imatinib and prior to failure was 
estimated US$2793 ($1612–$3125). The average monthly cost after failure increased to 
US$4706.18 ($3642–$5770), which represents an increment of 68.5% (t-test P < 0.001). 
The cost drivers of the increase are primarily: 1) inpatient visits, which increase from 
US$180 pre-failure to USD$367 post-failure, and 2) resources used in medical monitor-
ing and CML treatment, which increase from US$3678 pre-failure to US$4338 post-
failure per month. CONCLUSIONS: Once patients are resistant or intolerant to 
imatinib, their cost of treatment increases through additional demand for medical 
resources at Mexican public health care institutions.
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OBJECTIVES: To assess treatment costs per overall platelet response with 
romiplostim+concurrent treatment vs. placebo+concurrent treatment in chronic adult ITP, 
from a national payer perspective in Spain. METHODS: Platelet response was deﬁ ned as 
a platelet count of ≥50×109/L. Overall platelet response rates to romiplostim and placebo 
were used for the analysis and derived from two parallel clinical trials in splenectomized 
and non-splenectomized ITP patients [1]. All patients were allowed to enter on concurrent 
ITP medication (danazol, corticosteroids, azathioprine) and receive rescue medication (eg, 
intravenous immunoglogulins). Treatment costs were calculated over the 24-week clinical 
trial period and included intervention, rescue medication and management of bleeding-
related events. Costs were based on the 2009 national reimbursement list. Mean treatment 
cost per response was calculated for overall population, and for splenectomized and non-
splenectomized patients. RESULTS: Cost per response was substantially lower for romip-
lostim compared to placebo. Overall response rate was 83% for romiplostim and 7% for 
placebo (splenectomized patients 79% vs. 0%, non-splenectomized patients 88% vs. 14%, 
respectively). Mean treatment costs were c15,781 for romiplostim and c8,111 for placebo 
(splenectomized patients c15,436 vs. c10,263, non-splenectomized patients c16,125 vs. 
c5,958, respectively). Cost per response with romiplostim was c19,013 compared to 
c115,871 with placebo (splenectomized patients c19,539 vs. inﬁ nite cost/response, non-
splenectomized patients c18,324 vs. c42,557, respectively). The main cost-offsets were 
due to reduced immunoglobulin rescue use. CONCLUSIONS: Romiplostim represents an 
efﬁ cient use of health care resources in both splenectomized and non-splenectomized ITP 
patients for the Spanish health care system, leading to a signiﬁ cant improvement in manag-
ing a disease with a limited number of existing effective therapies. [1] Kuter et al. Lancet 
2008;371:395–403.
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OBJECTIVES: Chronic pain is gaining importance as a major cost factor in health 
care. To gather information about analgesic pharmacotherapy of patients with chronic 
pain and perform cost estimations to guide future cost-effectiveness research in the 
area. METHODS: Data from patients aged above 44 years suffering from any chronic 
condition and receiving regular analgesic pharmacotherapy (≥6 months) who attended 
health care facilities within the area of Badalona during 2008 were collected in a 
retrospective study. Morbidity proﬁ les were deﬁ ned according to treatment setting 
(pain unit, hospital), WHO analgesic stage (1–2 versus 3), and a raw cost model based 
on resource use and work absenteeism was applied. Patients attending the pain unit 
or the hospital were considered undertreated if they were on stage 1–2 analgesics. 
Multiple regression was used to compare costs between undertreated and non-under-
treated patients among those attending the pain unit or the hospital. RESULTS: Just 
410 out of 18,157 patients ascertained (2.3%) were on stage 3 analgesics. Direct 
health care costs were greater in patients on Step 3 analgesics (mean [SD]: 5,505.6 
[5,046.4] ) than in patients on Steps 1 and/or 2 analgesics (c2,407.4 [2,436.2]), but 
not indirect costs (c258.5 [1,578.4] vs. c279.5 [1,423.6], respectively). Of patients 
attended in the pain unit and the hospital, 2.3% and 20.1%, respectively, were con-
sidered undertreated. Regression analyses revealed even greater costs in the subgroup 
of undertreated patients. CONCLUSIONS: Conclusion: Stage 3 analgesics are barely 
used. Up to one-ﬁ fth of patients may be undertreated, and prompted greater costs 
than those judged as properly treated. Regression analyses did not clarify what propor-
tion of their cost excess was attributable to undertreatment.
